Latest Decision Biomarkers News
Nov 11, 2015
Jan 06, 2010 NEW YORK (GenomeWeb News) – Protein biomarker technology firm Decision Biomarkers has closed up shop and filed for Chapter 7 bankruptcy. Decision, based in Waltham, Mass., filed for bankruptcy on Dec. 22 in US Bankruptcy Court in Boston. Decision's website indicates that the company had closed its doors as of Dec. 2, 2009. "There are several companies interested in the technology and we are hopeful the business will be reconstituted in the near future," Decision said on its website. Get the full story
Decision Biomarkers Frequently Asked Questions (FAQ)
When was Decision Biomarkers founded?
Decision Biomarkers was founded in 2003.
Where is Decision Biomarkers's headquarters?
Decision Biomarkers's headquarters is located at 150 Bear Hill Road, Waltham.
What is Decision Biomarkers's latest funding round?
Decision Biomarkers's latest funding round is Asset Sale.
How much did Decision Biomarkers raise?
Decision Biomarkers raised a total of $15.1M.
Who are the investors of Decision Biomarkers?
Investors of Decision Biomarkers include Courtagen Life Sciences, Oxford Bioscience Partners, Rock Maple Ventures and Fletcher Spaght Ventures.
Who are Decision Biomarkers's competitors?
Competitors of Decision Biomarkers include HTG Molecular Diagnostics, Gyros, Pieris, Zyomyx, Intelligent Bio-Systems and 7 more.
Compare Decision Biomarkers to Competitors
Carna Biosciences is a clinical-stage biopharmaceutical company. It discovers and develops therapies to treat serious unmet medical needs, focusing on small-molecule drugs, mainly targeting protein kinases and epidermal growth factor (EGF) family molecules for their role in diseases such as cancer, inflammation, and dermatitis. It was founded in 2003 and is based in Kobe, Japan.
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
Zyomyx is a privately held diagnostics company. It innovates develops and commercializes diagnostic platforms. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development of affordable, disposable point-of-care diagnostic products, designed to increase access to testing. Zyomyx's first product is an advanced but simple and inexpensive CD4 T-cell point-of-care test that will be launched globally and is configured to meet the needs of developing countries. The company was founded in 1998 and is based in Fremont, California.
PharmaSelex (fka:GPC-Rx) focuses on the structure prediction of G-protein coupled receptors (GPCRs) to develop new GPCR-targeting drugs with reduced toxicity and enhanced selectivity. GPCRs are cell surface receptors that transmit chemical messages across the cell membrane. GPCRs have a complex structure that spans the cellular membrane seven times and is therefore difficult to predict. Due to their mediation of numerous critical physiological functions, GPCRs are involved in major disease areas including cardiovascular, metabolic, neurodegenerative, psychiatric, cancer, and infectious diseases. To facilitate the development of GPCR-targeting drugs, GPC-Rx aims to predict the structures of apo and ligand-bound GPCRs. The structure of GPCRs will permit rational design and optimization of drug candidates of many disease targets. GPC-Rx's technology was developed in the laboratory of Dr. William Goddard Ph.D. at California Institute of Technology. The Goddard group has established and validated methods to generate 3D-structures of GPCRs and their complexes with known ligands.
PrognostiX is a Cleveland, Ohio based company involved in the development of molecular biomarkers that aid in the diagnosis and treatment of cardiovascular disease. The company has developed the CardioMPO Test; which is an enzyme immunoassay used to evaluate patients that are at risk for major adverse cardiac events.
SistemRNA is a healthcare company developing a microRNA-based platform that screens compound databases against the microRNA expression profiles of leading drugs, to find compounds with similar profiles. Per Sistemic, this process generates information on biological differences, mechanism of action and potential new targets.